Bristol-Myers Squibb has reached a confidential settlement with Otsuka Pharmaceuticals Co. Ltd. over its antipsychotic medication, Abilify

Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. have reached a confidential settlement regarding the drug Abilify with plaintiffs in the multi district litigation (MDL) on February 26, 2019. The drug is meant for antipsychotic purposes to treat schizophrenia and bipolar disorders. However, Abilify has also been known to cause side effects of compulsive behaviors, such as gambling, binge eating and compulsive sexual urges in patients who took the medication. Rather than continue litigation or express liability, the companies have agreed to settle for an undisclosed amount. This settlement comes after having previously settled in April of 2018 in three bellwether trials for undisclosed amounts as well.

About the author